Conference Proceedings

Durable Suppression of Disease Activity by Alemtuzumab in the Absence of Continuous Treatment Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy (CARE-MS II)

Richard AL Macdonell, Christopher LaGanke, Jerome De Seze, Mark S Freedman, Mario Habek, Raymond MM Hupperts, Volker Limmroth, Krzysztof W Selmaj, David H Margolin, Karthinathan Thangavelu, Eva Havrdova

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2017